Medigen Vaccine Biologics (6547) — Working Capital to Net Assets Ratio
Medigen Vaccine Biologics (6547) has a Working Capital to Net Assets ratio of 62.6% as of December 2025. Working capital of NT$2.18 Billion (current assets of NT$2.36 Billion minus current liabilities of NT$185.04 Million) is measured against net assets of NT$3.48 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Medigen Vaccine Biologics (6547) flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Medigen Vaccine Biologics Working Capital to Net Assets (2012–2025)
This chart shows how Medigen Vaccine Biologics's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 62.6%, reflecting working capital of NT$2.18 Billion against net assets of NT$3.48 Billion TWD. See 6547 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Medigen Vaccine Biologics (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Medigen Vaccine Biologics from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Medigen Vaccine Biologics stock valuation.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 62.6% | NT$2.18 Billion | NT$3.48 Billion | NT$2.36 Billion | NT$185.04 Million | ▲ +1.7 pp |
| 2024 | 60.8% | NT$2.34 Billion | NT$3.85 Billion | NT$2.56 Billion | NT$214.22 Million | ▼ -1.8 pp |
| 2023 | 62.6% | NT$2.41 Billion | NT$3.85 Billion | NT$4.40 Billion | NT$1.99 Billion | ▼ -38.9 pp |
| 2022 | 101.6% | NT$5.11 Billion | NT$5.03 Billion | NT$5.46 Billion | NT$355.23 Million | ▲ +31.4 pp |
| 2021 | 70.2% | NT$3.28 Billion | NT$4.68 Billion | NT$3.72 Billion | NT$439.09 Million | ▲ +11.3 pp |
| 2020 | 58.8% | NT$1.85 Billion | NT$3.14 Billion | NT$2.01 Billion | NT$160.97 Million | ▲ +37.6 pp |
| 2019 | 21.3% | NT$291.10 Million | NT$1.37 Billion | NT$518.93 Million | NT$227.83 Million | ▼ -18.1 pp |
| 2018 | 39.4% | NT$634.88 Million | NT$1.61 Billion | NT$772.42 Million | NT$137.54 Million | ▲ +4.1 pp |
| 2017 | 35.3% | NT$536.43 Million | NT$1.52 Billion | NT$646.13 Million | NT$109.70 Million | ▲ +14.8 pp |
| 2016 | 20.5% | NT$300.57 Million | NT$1.47 Billion | NT$337.39 Million | NT$36.82 Million | ▼ -18.8 pp |
| 2015 | 39.3% | NT$528.04 Million | NT$1.34 Billion | NT$592.00 Million | NT$63.95 Million | ▼ -11.6 pp |
| 2014 | 50.9% | NT$548.76 Million | NT$1.08 Billion | NT$600.10 Million | NT$51.35 Million | ▼ -18.2 pp |
| 2013 | 69.1% | NT$316.39 Million | NT$457.94 Million | NT$335.85 Million | NT$19.46 Million | ▲ +51.2 pp |
| 2012 | 17.9% | NT$22.90 Million | NT$128.00 Million | NT$45.05 Million | NT$22.15 Million | — |